Relay Therapeutics appoints Claire Mazumdar to board; Jami Ruben resigns

Relay Therapeutics, Inc.

Jami Ruben resigned as Class III director and Audit Committee member effective June 8, 2025; no dispute or disagreement.
Claire Mazumdar, Ph.D., appointed as Class III director and Audit Committee chair effective June 9, 2025.
Dr. Mazumdar is founding CEO of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company.
She received an initial option to purchase 421,241 shares at $3.36/share, vesting monthly over three years.
Board determined Dr. Mazumdar is independent under Nasdaq listing standards.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Claire Mazumdar

Class III Director

RLAY · Relay Therapeutics, Inc.

Effective: 2025-06-09
Filed: June 11, 2025, 7:59 PM ET

On June 9, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Claire Mazumdar, Ph.D., MBA as a member of the Board, effective as of June 9, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Claire Mazumdar was appointed as Class III Director at Relay Therapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On June 9, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Claire Mazumdar, Ph.D., MBA as a member of the Board, effective as of June 9, 2025.

View on SEC.gov

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-139146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.